Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus.

Shimada Y, Asanuma YF, Yokota K, Yoshida Y, Kajiyama H, Sato K, Akiyama Y, Mimura T.

Mod Rheumatol. 2014 Jan;24(1):78-85. doi: 10.3109/14397595.2013.852837.

PMID:
24261762
2.

Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.

Cieślik P, Hrycek A.

Autoimmunity. 2015 Jun;48(4):242-50. doi: 10.3109/08916934.2014.983264. Epub 2014 Nov 17.

PMID:
25401491
3.

Carotid subclinical atherosclerosis is associated with disease activity but not vitamin D in Korean systemic lupus erythematosus.

Jung JY, Koh BR, Bae CB, Kim HA, Suh CH.

Lupus. 2014 Dec;23(14):1517-22. doi: 10.1177/0961203314544185. Epub 2014 Jul 24.

PMID:
25059488
4.

Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Mikołajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D, Sliwa T, Pryjma JR, Guzik TJ.

Lupus. 2016 Jan;25(1):18-27. doi: 10.1177/0961203315598014. Epub 2015 Aug 6.

PMID:
26251402
5.

Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients.

Katakami N, Kaneto H, Sakamoto F, Takahara M, Irie Y, Fujisawa K, Miyashita K, Yasuda T, Matsuoka TA, Yoshiuchi K, Sakamoto K, Kuroda A, Matsuhisa M, Kosugi K, Shimomura I.

Diabetes Res Clin Pract. 2013 Feb;99(2):185-91. doi: 10.1016/j.diabres.2012.11.020. Epub 2012 Dec 13.

PMID:
23245734
6.

Predictors of carotid atherosclerosis in systemic lupus erythematosus.

Maksimowicz-McKinnon K, Magder LS, Petri M.

J Rheumatol. 2006 Dec;33(12):2458-63. Epub 2006 Oct 1.

PMID:
17014002
7.

Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.

Zhang CY, Lu LJ, Li FH, Li HL, Gu YY, Chen SL, Bao CD.

J Clin Rheumatol. 2009 Apr;15(3):111-6. doi: 10.1097/RHU.0b013e31819d8489.

PMID:
19300290
8.

Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A.

Oryoji K, Kiyohara C, Horiuchi T, Tsukamoto H, Niiro H, Shimoda T, Akashi K, Yanase T.

Mod Rheumatol. 2014 Jan;24(1):86-92. doi: 10.3109/14397595.2013.852838.

PMID:
24261763
9.

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH.

Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.

10.

Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile.

Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, Valente M, Cattin L, Guarnieri G, Barazzoni R.

Clin Exp Med. 2009 Sep;9(3):243-8. doi: 10.1007/s10238-009-0039-z. Epub 2009 Feb 24.

PMID:
19238513
11.

IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus.

Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, Shoenfeld Y, Doria A.

Ann Rheum Dis. 2010 Sep;69(9):1704-10. doi: 10.1136/ard.2009.117804. Epub 2010 May 3.

PMID:
20439287
12.

Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease.

Hollan I, Bottazzi B, Cuccovillo I, Førre ØT, Mikkelsen K, Saatvedt K, Almdahl SM, Mantovani A, Meroni PL; Feiring Heart Biopsy Study Group.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):378-85. doi: 10.1002/acr.20094.

13.

Higher circulating levels of OxLDL % of LDL are associated with subclinical atherosclerosis in female patients with systemic lupus erythematosus.

Ahmad HM, Sarhan EM, Komber U.

Rheumatol Int. 2014 May;34(5):617-23. doi: 10.1007/s00296-013-2875-0. Epub 2013 Oct 8.

PMID:
24101173
14.

Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis.

Huang XL, Zhang L, Duan Y, Wang YJ, Wang J.

Arch Med Res. 2016 Apr;47(3):223-31. doi: 10.1016/j.arcmed.2016.05.006. Epub 2016 May 31. Review.

PMID:
27255354
15.

Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus.

Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE.

Arthritis Rheum. 2007 Oct;56(10):3412-9.

16.

Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Wong CK, Lun SW, Ko GT, Lam CW, Lam CS.

Scand J Rheumatol. 2010;39(1):42-9. doi: 10.3109/03009740903046668.

PMID:
20132070
17.

PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis.

Bassi N, Del Prete D, Ghirardello A, Gatto M, Ceol M, Zen M, Bettio S, Mantovani A, Iaccarino L, Punzi L, Doria A.

Clin Rev Allergy Immunol. 2015 Oct;49(2):217-26. doi: 10.1007/s12016-015-8476-9.

PMID:
25805362
19.

Pentraxin 3 Is Closely Associated With Tubulointerstitial Injury in Lupus Nephritis: A Large Multicenter Cross-Sectional Study.

Pang Y, Tan Y, Li Y, Zhang J, Guo Y, Guo Z, Zhang C, Yu F, Zhao MH.

Medicine (Baltimore). 2016 Jan;95(3):e2520. doi: 10.1097/MD.0000000000002520.

20.

PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation.

Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG, Manfredi AA, Mantovani A, Querini PR.

Arthritis Rheum. 2001 Dec;44(12):2841-50.

PMID:
11762945

Supplemental Content

Support Center